|
Video: What is a Stock Split?
|
|
Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A. According to our Sangamo Therapeutics stock split history records, Sangamo Therapeutics has had 0 splits. | |
|
Sangamo Therapeutics (SGMO) has 0 splits in our Sangamo Therapeutics stock split history database.
Looking at the Sangamo Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sangamo Therapeutics shares, starting with a $10,000 purchase of SGMO, presented on a split-history-adjusted basis factoring in the complete Sangamo Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$17.95 |
|
End price/share: |
$0.67 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-96.27% |
|
Average Annual Total Return: |
-28.03% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$373.17 |
|
Years: |
10.00 |
|
|
|
|
|